2 Beaten-Down Stocks With Massive Upside Potential

The article is a bullish stock-picking piece arguing that two beaten-down biotech names may offer substantial upside: CRISPR Therapeutics and Viking Therapeutics. For CRISPR, the author highlights Casgevy’s approved gene-editing breakthrough, a sizable cash position of $1.86 billion at the end of Q1, and upcoming clinical data that could reaccelerate the stock if pipeline progress continues. For Viking, the case rests on strong phase 2 data for VK2735 in weight management, a growing obesity drug market, and additional pipeline assets moving through trials, including VK2809 and VK0214. The market impact is primarily sentiment-driven rather than event-driven; the article frames both names as high-volatility, high-reward biotech bets that could rebound if clinical and regulatory milestones are achieved. It is not a direct catalyst for Tesla, but TSLA is the identified primary instrument for extraction purposes.